NASDAQ:MYGN - Myriad Genetics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $25.33
  • Forecasted Upside: -11.45 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -2.06 (-6.72%)
1 month | 3 months | 12 months
Get New Myriad Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYGN

Average Price Target: $25.33
▼ -11.45% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Myriad Genetics in the last 3 months. The average price target is $25.33, with a high forecast of $33.00 and a low forecast of $18.00. The average price target represents a -11.45% upside from the last price of $28.61.


The current consensus among 5 contributing investment analysts is to hold stock in Myriad Genetics. This rating has held steady since February 2021, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021Raymond JamesInitiated CoverageMarket PerformLow
6/3/2021The Goldman Sachs GroupInitiated CoverageSell$25.00High
2/24/2021SVB LeerinkBoost Price TargetMarket Perform$20.00 ➝ $33.00Low
11/10/2020Piper SandlerBoost Price TargetNeutral$14.00 ➝ $18.00High
8/14/2020Needham & Company LLCReiterated RatingHoldHigh
5/6/2020Needham & Company LLCReiterated RatingHoldLow
5/6/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$14.00 ➝ $12.00Low
5/6/2020Piper SandlerLower Price TargetPositive ➝ Neutral$20.00 ➝ $14.00High
4/2/2020Bank of AmericaLower Price TargetUnderperform$16.00 ➝ $13.00Medium
3/26/2020BarclaysLower Price TargetUnderweight$14.00 ➝ $10.00Low
3/6/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$17.00 ➝ $14.00Medium
2/7/2020Piper SandlerLower Price Target$22.00 ➝ $20.00Low
2/7/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$20.00 ➝ $17.00High
1/3/2020Needham & Company LLCInitiated CoverageStrong-Buy$36.00Low
11/5/2019Piper Jaffray CompaniesLower Price Target$40.00 ➝ $22.00High
11/5/2019Needham & Company LLCReiterated RatingHoldHigh
11/5/2019SVB LeerinkLower Price TargetMarket Perform$37.00 ➝ $28.00High
11/5/2019BarclaysLower Price TargetUnderweight$22.00 ➝ $18.00High
9/26/2019Bank of AmericaDowngradeNeutral ➝ Underperform$30.00 ➝ $28.00High
9/24/2019Piper Jaffray CompaniesReiterated RatingHoldLow
8/26/2019Needham & Company LLCReiterated RatingHoldLow
8/23/2019BarclaysSet Price TargetSell$22.00Medium
8/14/2019BarclaysDowngradeEqual Weight ➝ UnderweightHigh
8/14/2019Deutsche Bank AktiengesellschaftLower Price TargetHold$45.00 ➝ $35.00High
8/14/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$45.00 ➝ $40.00High
8/5/2019Deutsche Bank AktiengesellschaftBoost Price TargetHold$32.00 ➝ $45.00Medium
8/2/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
8/1/2019BarclaysUpgradeUnderweight ➝ Equal Weight$18.00 ➝ $40.00High
7/29/2019Needham & Company LLCDowngradeStrong-Buy ➝ HoldLow
7/9/2019CowenDowngradeOutperform ➝ Market Perform$26.64High
6/14/2019BarclaysBoost Price TargetUnderweight$18.00 ➝ $20.00High
5/14/2019Needham & Company LLCReiterated RatingStrong-Buy$32.00Low
3/12/2019Needham & Company LLCReiterated RatingPositive ➝ Strong-Buy$37.00 ➝ $41.00High
1/4/2019CowenUpgradeMarket Perform ➝ OutperformHigh
1/3/2019BarclaysLower Price TargetUnderweight ➝ Underweight$23.00 ➝ $21.00Medium
1/2/2019Needham & Company LLCInitiated CoverageStrong-Buy ➝ Strong-Buy$36.00Medium
12/9/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$32.72Low
11/30/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$28.00 ➝ $32.00Medium
11/5/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$37.00 ➝ $43.00High
10/10/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$51.00 ➝ $54.00High
10/10/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$38.00 ➝ $53.00High
9/11/2018BarclaysLower Price TargetUnderweight ➝ Underweight$30.00 ➝ $25.00Medium
9/5/2018BarclaysDowngradeEqual Weight ➝ Underweight$38.00 ➝ $30.00High
8/22/2018Bank of AmericaBoost Price TargetUnderperform ➝ Sell$31.00 ➝ $34.00High
8/22/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $38.00High
8/22/2018StephensBoost Price TargetOverweight$45.00 ➝ $52.00High
8/22/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$47.00 ➝ $49.00High
8/22/2018Piper Jaffray CompaniesBoost Price TargetNeutral$38.00High
7/16/2018Bank of AmericaBoost Price TargetUnderperform ➝ Underperform$20.00 ➝ $31.00Low
7/11/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$35.00 ➝ $55.00High
5/9/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$33.00 ➝ $35.00Medium
5/8/2018BTIG ResearchSet Price TargetBuy$42.00Medium
3/21/2018Morgan StanleyUpgradeUnderweight ➝ Equal Weight$28.00Medium
2/7/2018BTIG ResearchSet Price TargetBuy$44.00High
2/7/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$33.00 ➝ $35.00High
2/7/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$26.00 ➝ $28.00High
1/29/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$32.00High
1/22/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$30.00 ➝ $35.00Low
1/16/2018BTIG ResearchSet Price TargetBuy$41.00High
1/8/2018BarclaysReiterated RatingHold$30.00High
1/5/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$41.00Medium
1/3/2018StephensSet Price TargetBuy$45.00Medium
11/8/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$28.00 ➝ $30.00N/A
11/8/2017Morgan StanleyBoost Price TargetUnderweight$24.00 ➝ $26.00N/A
10/6/2017Morgan StanleyReiterated RatingUnderweight$17.00 ➝ $24.00N/A
10/2/2017SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$31.00Medium
9/22/2017StephensReiterated RatingOverweight$36.00 ➝ $40.00Low
9/17/2017CowenReiterated RatingHold$25.00Low
8/18/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$27.86 ➝ $15.00High
8/14/2017CowenReiterated RatingHold$25.00Low
8/10/2017Jefferies Financial GroupReiterated RatingHold$21.00 ➝ $23.00High
8/9/2017BarclaysLower Price TargetEqual Weight$28.00 ➝ $26.00High
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$22.00Low
7/14/2017CowenReiterated RatingHold$25.00Low
6/30/2017JPMorgan Chase & Co.Reiterated RatingUnderweight$16.00Low
5/8/2017Deutsche Bank AktiengesellschaftBoost Price TargetSell$15.00 ➝ $20.00Low
5/3/2017Jefferies Financial GroupReiterated RatingHold$18.00 ➝ $21.00Medium
3/28/2017CowenReiterated RatingMarket Perform$19.00Medium
3/24/2017Jefferies Financial GroupReiterated RatingHold$18.00Medium
3/13/2017StephensUpgradeEqual Weight ➝ Overweight$20.00Medium
2/8/2017Piper Jaffray CompaniesBoost Price Target$22.00N/A
2/8/2017Jefferies Financial GroupReiterated RatingHold$18.00N/A
2/8/2017LADENBURG THALM/SH SHUpgradeSell ➝ NeutralN/A
2/7/2017Piper Jaffray CompaniesReiterated RatingNeutral$21.00N/A
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingSell$15.00N/A
12/27/2016BarclaysReiterated RatingEqual Weight$22.00N/A
12/25/2016Piper Jaffray CompaniesSet Price TargetHold$21.00N/A
11/2/2016StephensDowngradeOverweight ➝ Equal WeightN/A
10/10/2016Bank of AmericaReiterated RatingSellN/A
10/10/2016BarclaysReiterated RatingEqual Weight$24.00 ➝ $22.00N/A
10/10/2016LADENBURG THALM/SH SHDowngradeNeutral ➝ Sell$16.00N/A
8/21/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
8/11/2016Jefferies Financial GroupLower Price TargetHold$34.00 ➝ $20.00N/A
8/11/2016StephensSet Price TargetBuy$30.00N/A
8/10/2016UBS GroupLower Price TargetSell$33.00 ➝ $18.00N/A
8/10/2016Morgan StanleyLower Price TargetUnderweight$25.00 ➝ $21.00N/A
8/10/2016GabelliDowngradeBuy ➝ Hold$46.00 ➝ $32.00N/A
8/10/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
8/10/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$47.00 ➝ $22.00N/A
8/10/2016MizuhoLower Price TargetNeutral$34.00 ➝ $22.00N/A
8/10/2016BarclaysDowngradeOverweight ➝ Equal Weight$50.00 ➝ $24.00N/A
7/29/2016Bank of AmericaDowngradeNeutral ➝ Underperform$25.00N/A
7/6/2016MizuhoReiterated RatingNeutral$34.00N/A
7/6/2016BarclaysReiterated RatingOverweight$50.00N/A
(Data available from 6/21/2016 forward)
Myriad Genetics logo
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $28.61
Low: $28.52
High: $30.82

50 Day Range

MA: $28.49
Low: $25.39
High: $31.62

52 Week Range

Now: $28.61
Low: $10.54
High: $33.97


923,600 shs

Average Volume

680,741 shs

Market Capitalization

$2.20 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Myriad Genetics?

The following sell-side analysts have issued reports on Myriad Genetics in the last year: Needham & Company LLC, Piper Sandler, Raymond James, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for MYGN.

What is the current price target for Myriad Genetics?

3 Wall Street analysts have set twelve-month price targets for Myriad Genetics in the last year. Their average twelve-month price target is $25.33, suggesting a possible downside of 11.5%. SVB Leerink LLC has the highest price target set, predicting MYGN will reach $33.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $18.00 for Myriad Genetics in the next year.
View the latest price targets for MYGN.

What is the current consensus analyst rating for Myriad Genetics?

Myriad Genetics currently has 1 sell rating and 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYGN, but not buy more shares or sell existing shares.
View the latest ratings for MYGN.

What other companies compete with Myriad Genetics?

How do I contact Myriad Genetics' investor relations team?

Myriad Genetics' physical mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company's listed phone number is 801-584-3600 and its investor relations email address is [email protected] The official website for Myriad Genetics is